Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein
View Patent ↗The present invention relates to compositions and methods for treating HER2/Neu (ERBB2) expressing cancer cells. In some embodiments, the invention includes an isolated T cell receptor (TCR) having high affinity for and that specifically binds ERBB2 369-377 epitope on a target cell. Other embodiments include a T cell or a population of T cells modified to express ERBB2-specific TCR. Further embodiments include methods of using ERBB2-specific TCR gene transfer for treating ERBB2 expressing cancer cells. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy.
1. A method of inhibiting the growth of tyrosine-protein kinase HER2/Neu (ERBB2)-expressing tumor cells in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a T cell transduced with a recombinant polynucleotide encoding a T cell receptor (TCR), wherein the recombinant polynucleotide encodes a TCR alpha chain having the sequence of SEQ ID NO: 2 or 6 and a TCR beta chain having the sequence of SEQ ID NO: 4 or 7, wherein the recombinant polynucleotide expresses a functional ERBB2-specific TCR reactive with an HLA-A2+ restricted ERBB2 epitope, and wherein the growth of the ERBB2-expressing tumor cells is inhibited.
2. The method of claim 1 , wherein the cancer is a cancer of the breast, ovary, stomach, kidney, colon, bladder, salivary gland, endometrium, pancreas or lung.
3. The method of claim 1 , wherein the modified cell is a CD8+ T cell.
4. The method of claim 1 , wherein the modified cell is autologous with respect to the human undergoing treatment.
5. A method of inhibiting the growth of tyrosine-protein kinase HER2/Neu (ERBB2)-expressing tumor cells in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a T cell transduced with a recombinant polynucleotide encoding a T cell receptor (TCR), wherein the recombinant polynucleotide encodes a TCR alpha chain having the sequence of SEQ ID NO: 2 and a TCR beta chain having the sequence of SEQ ID NO: 4, wherein the recombinant polynucleotide expresses a functional ERBB2-specific TCR reactive with an HLA-A2+ restricted ERBB2 epitope, and wherein the growth of the ERBB2-expressing tumor cells is inhibited.
6. The method of claim 5 , wherein the cancer is a cancer of the breast, ovary, stomach, kidney, colon, bladder, salivary gland, endometrium, pancreas or lung.
7. The method of claim 5 , wherein the modified cell is a CD8+ T cell.
8. The method of claim 5 , wherein the modified cell is autologous with respect to the human undergoing treatment.